Background. Contemporary data on venous thromboembolism (VTE) risk in dialysis patients are limited. Our objective was to determine the risk and complications of VTE among incident maintenance dialysis patients. Methods. We performed a retrospective cohort study using administrative databases. We included adult incident dialysis patients from 2004 to 2010 (n ¼ 13 315). Dialysis patients were age-and sex-matched to individuals of the general population using a 1:4 ratio (n ¼ 53 260). We determined the 3-year cumulative incidence and incidence rate (IR) of VTE, pulmonary embolism (PE) and deep venous thrombosis (DVT). We examined outcomes of bleeding and all-cause mortality following a VTE event among matched dialysis patients who did and did not experience a VTE. We used Cox proportional hazards regression models, stratified on matched sets, to calculate the hazard ratios (HRs) for all outcomes of interest. Results. VTE occurred in 1114 (8.4%) dialysis patients compared with 1233 (2.3%) individuals in the general population {IR 37.1 versus 8.1 per 1000 person-years; HR 4.5 [95% confidence interval (CI) 4.1-4.9]; adjusted HR 2.9 (95% CI 2.6-3.4)}. Both components of VTE [PE and DVT; adjusted HR 4.0 (95% CI 2.9-5.6) and HR 2.8 (95% CI 2.4-3.2), respectively] occurred more frequently in dialysis patients. Compared with dialysis patients without a VTE, those with a VTE had a higher risk of bleeding [adjusted HR 2.0 (95% CI 1.3-2.9)] and all-cause mortality [adjusted HR 2.4 (95% CI 2.0-2.8)]. Conclusions. VTE is common in dialysis patients and confers a high risk of major bleeding and all-cause mortality. Thromboprophylaxis and VTE treatment studies in dialysis patients are needed.
I N T R O D U C T I O N
Chronic kidney disease (CKD) has been linked to a hypercoagulable state [1, 2] . Multiple studies have found that CKD [defined by proteinuria or reduced estimated glomerular filtration rate (eGFR)] increases the risk for venous thromboembolism (VTE) [comprising deep venous thrombosis (DVT) and pulmonary embolism (PE)] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Kidney disease defined by nephrotic syndrome is a well-established risk factor for VTE [4, 8] . Recent data suggest that even low levels of proteinuria increase the risk for VTE [7] . For CKD not requiring dialysis (CKD Stages 2-4), studies suggest that VTE risk increases in a graded fashion with declining eGFR, but the data are conflicting [6, 12] . The high risk of VTE appears to remain among patients with kidney failure requiring dialysis. A large study conducted using the US Renal Data System (USRDS) demonstrated an age-adjusted 2.3-fold increased risk of PE (compared with the general population) among dialysis patients initiating dialysis in 1996 [11] . Small cohort studies, limited to critically ill patients, that examined the association of VTE and DVT with end-stage renal disease (ESRD) have shown mixed results [5, 13, 14] . We are aware of only one prior study that examined the risk of VTE (both PE and DVT) in a general maintenance dialysis population. This study demonstrated a > 5-fold increased risk compared with the general population; however, the study size was relatively small (n ¼ 455, with only 15 VTE events) and complications following a VTE event after starting maintenance dialysis were not examined [10] .
Contemporary data on the risk of VTE in the dialysis population are limited. Characterization of the risk will help inform the development of preventive and treatment strategies. With this in mind, we designed a large retrospective study with the primary aim of determining the risk of VTE among incident maintenance dialysis patients compared with age-and sexmatched members of the general population. We further examined secular trends, the risk in specific subgroups and post-VTE outcomes of recurrence, major bleeding and all-cause mortality.
M A T E R I A L S A N D M E T H O D S

Design and setting
We conducted a population-based retrospective cohort study using administrative health care databases linked via unique encoded identifiers held at the Institute for Clinical Evaluative Sciences (ICES) in Ontario, Canada. The study was conducted according to a prespecified protocol that was approved by the Research Ethics Board at Sunnybrook Health Sciences Centre (Toronto, Ontario, Canada). The reporting of this study follows the Reporting of Studies Conducted Using Observational Routinely Collected Health Data (RECORD) guidelines for observational studies (Supplementary Appendix A) [15] .
Data sources
Incident maintenance dialysis patients were identified from the Canadian Organ Replacement Register (CORR), which captures all dialysis and kidney transplant activities in Canada. CORR was also used to identify patients with a prior history of a kidney transplant. Demographics and vital status information were obtained from the Ontario Registered Persons Database. Diagnostic and procedural information from all hospitalizations was determined using the Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD). Diagnostic information from emergency room visits was determined using the CIHI National Ambulatory Care Reporting System (NACRS). Information was also obtained from the Ontario Health Insurance Plan (OHIP) database, which contains all health claims for inpatient and outpatient physician services. Whenever possible, we defined patient characteristics and outcomes using validated codes (Supplementary Appendix B).
Study cohort
Dialysis patients. We included all adult permanent residents of Ontario who initiated maintenance dialysis between 1 January 2004 and 31 December 2010. For the primary analysis, the date of dialysis initiation served as the start of follow-up (index date, i.e. cohort entry date). We excluded all dialysis patients who had received a prior kidney transplant and those who had previously been on dialysis. Patient selection is outlined in Supplementary data, Figure S1 . A patient's assigned dialysis modality and dialysis access were determined at the time of dialysis initiation. Arteriovenous (AV) fistulas and grafts were grouped together due to the low prevalence of AV grafts in Canada.
Nondialysis comparator cohort. We randomly assigned an index date to the entire adult general population in Ontario according to the distribution of index dates in the dialysis patients.
We excluded residents who were <18 years of age on their assigned index date and with a history of CKD, including those with a prior history of kidney transplant or dialysis. Incident chronic dialysis patients were matched to members of the general population using a 1:4 ratio based on age (62 years), sex and index date (61 year).
Assessment of VTE
We assessed individuals for evidence of a VTE within 3 years of the index date. An outcome of VTE was defined as evidence of a diagnostic code for DVT or PE during a hospital admission, emergency department visit or outpatient visit as specified in Supplementary Appendix B. As a surrogate for fatal VTE, we examined death within 30 days of VTE. To avoid the potential inclusion of AV fistula or graft thrombosis as a VTE event, all events with a code for AV fistula/graft angioplasty or thrombectomy within 0-15 days following the date of the VTE were excluded (n ¼ 37). An observation period of 3 years was selected as a period of follow-up that could be reasonably adopted in a future trial testing interventions to prevent VTE.
Outcomes post-VTE
We compared maintenance dialysis patients who had a VTE in the 3 years following dialysis initiation with those who had not. The index date was the date of the initial VTE. Dialysis patients without an event were randomly assigned a new index date based on the distribution of time to VTE in the affected dialysis patients. Dialysis patients with a VTE were then matched 1:1 to those without a VTE based on age (62 years), sex, time from dialysis initiation to index date (62 years) and index date (62 years). Secondary outcomes included a major bleeding event associated with a hospitalization (upper or lower gastrointestinal, intracerebral, subarachnoid and other nontraumatic intracranial) and all-cause mortality (diagnostic and procedural codes in Supplementary Appendix B).
Statistical analysis
We used standardized differences to compare baseline characteristics between all dialysis patients and the matched general population. Standardized differences were also used to compare baseline characteristics of dialysis patients across eras. Standardized differences >10% were considered statistically significant [16] . Patients were followed until one of the following occurred: end of the prespecified follow-up period, outcome of interest or death. Dialysis patients were not censored at the time of kidney transplantation so that our risk estimates of VTE following dialysis initiation could be more easily translated to the clinical setting. A sensitivity analysis censoring dialysis patients at the time of kidney transplantation was performed.
To determine the risk of VTE, we defined the cumulative incidence as the proportion of individuals who experienced a VTE within 3 years of the starting dialysis (maximum follow-up date 31 December 2013). We calculated the incidence rate (IR) defined as the rate per 1000 person-years of follow-up. We used Cox proportional hazards regression models, stratified on matched sets, to calculate hazard ratios (HRs) for the outcomes of VTE, PE, DVT and death within 30 days of VTE. We adjusted for comorbidities as specified in Table 2 . We performed subgroup analyses by era of dialysis initiation (2004-05, 2006-07, 2008-10) , initial dialysis modality [hemodialysis (HD) versus peritoneal dialysis (PD)], initial dialysis access [central venous catheter (CVC) versus AV fistula/graft or PD catheter], age at dialysis initiation, history of recent hospitalization (within 90 days prior to dialysis initiation) and provoked (history of thrombophilia, recent surgery or fracture or history of cancer within 5 years) versus unprovoked VTE. Incidence rate ratios (IRRs) (adjusting for age and sex) were calculated using Poisson regression models comparing dialysis patient subgroups.
We determined the incidence of recurrent VTE at > 1 year following the initial VTE event. A period of > 1 year was selected to help ensure that the presence of a repeat diagnostic code for VTE was due to a true new event and not simply a follow-up visit for the original event. To determine the risk of major bleeding and all-cause mortality, we used Cox proportional hazards regression models, stratified on matched sets, to calculate HRs. We adjusted for demographics and comorbidities as specified in Table 4 . The maximum follow-up date for this analysis was 31 March 2015.
R E S U L T S
Baseline characteristics
Cohort selection is outlined in Supplementary data, Figure S1 . Our final cohort included 13 315 adult incident maintenance dialysis patients. We were able to successfully match all included dialysis patients with individuals of the general population (1:4 matching). The baseline characteristics of the dialysis and matched general population individuals are outlined in Table 1 . The median age was 67 years [interquartile range (IQR) 55-77] and 59% of individuals were male. Compared with matched members of the general population, dialysis patients had a higher prevalence of all examined comorbidities and were more likely to have a prior history of VTE (9.0% versus 2.7%) and a history of recent surgery (56.8% versus 5.7%).
The majority of included dialysis patients were Caucasian (71.4%). The most common cause of ESRD was diabetes (36.3%). The most common dialysis modality was HD (79.0%) and most patients initiated dialysis with a CVC (67.8%) (Supplementary data, Table S1 ).
The risk of VTE among dialysis patients
Among included dialysis patients, 5016 (37.7%) patients died, 1598 (12%) patients were transplanted and 1114 (8.4%) developed a VTE during the 3-year follow-up period. The median time from dialysis start to VTE was 1.0 (IQR 0.3-1.9) year. The IR of VTE was highest during the first 6 months following dialysis initiation (IR at 0-6 months, >6 months -1 year and >1 -3 years 58.6, 31.0 and 30.9 per 1000 person-years, respectively). The majority of VTE events were DVTs (with or without a PE) [n ¼ 981 (7.4%)]. The 3-year cumulative incidence and IR of VTE in the dialysis and matched general population groups are presented in Table 2 . The IR of VTE was 37. In a sensitivity analysis censoring for kidney transplantation, 1060 (8.0%) dialysis patients (IR 37.0 per 1000 person-years) developed a VTE during the 3-year follow-up period.
Secular trends in VTE risk among dialysis patients
The baseline characteristics of the dialysis cohort by era of dialysis initiation (2004-05, 2006-07, 2008-10) are presented in Supplementary data, Table S1 . Demographic characteristics, cause of ESRD and initial dialysis modality and access remained similar across eras. There was a higher prevalence of prior cancer and recent surgery in the most recent era; the prevalence of all other comorbidities remained similar across eras. The IR of Cox proportional hazards regression models, stratified on matched sets, adjusted for thrombophilia (y/n), recent surgery (y/n), recent fracture (y/n), history of cancer (y/n), prior VTE (y/n), myocardial infarction (y/n), congestive heart failure (y/n), diabetes (y/n), chronic obstructive pulmonary disease (y/n), ischemic stroke (y/n), peripheral vascular disease (y/n) and hypertension (y/n). PY, person-years; y, yes; n, no. Table S3 ).
Risk of VTE in dialysis patient subgroups of interest
The risk of VTE was lower among patients whose initial dia- (Table 3) . Similar results were seen when the outcome of DVT was examined separately. The IR of DVT was higher among dialysis patients with a recent hospitalization, but the result was not statistically significant [IRR 1.1 (95% CI 1.0-1.3)]. When the outcome of PE was examined separately, the risk was lower among patients whose initial dialysis modality was PD [IRR 0.6 (95% CI 0.4-0. Tables S2 and S3) .
Post-VTE complications in dialysis patients
Of the 1114 dialysis patients who developed a VTE, 192 (17.2%) (IR 70.0 per 1000 person-years) experienced a recurrent event >1 year after the initial VTE. The median time to recurrence at >1 year following the initial event was 2.0 (IQR 1.3-3.1) years. Thirty-two (16.7%) of the recurrent events were a PE. Compared with dialysis patients without a VTE, dialysis patients with a VTE had a higher risk of major bleeding (Table 4) .
D I S C U S S I O N
In this retrospective study including >13 000 adult incident dialysis patients, we found that 1114 (8.4%) patients developed a VTE in the 3 years following dialysis initiation. The risk of VTE was highest in the first 6 months following dialysis initiation. The incidence of VTE, PE, DVT and death within 30 days of VTE were all >4-fold higher in the dialysis patient population compared with a matched general population sample, and this increased risk persisted upon adjustment for comorbidities. The risk of VTE in dialysis patients remained stable over the duration of the last decade. Dialysis patients with a CVC had the highest risk of VTE. Our data illustrate the high risk of VTE among incident dialysis patients and that a VTE event confers a high risk of recurrence and subsequent clinical complications.
We found a higher risk of events compared with prior studies. We report an IR of VTE of 37.1 compared with 12.3 per 1000 person-years in a European dialysis cohort [10] . Similarly, we found that PE was more common compared with a report from the USRDS (6.5 versus 1.5 per 1000 person-years). Possibilities for these differences include older age and higher comorbidity burden in our contemporary dialysis cohort. CVC use is more widespread in the Canadian dialysis population compared with some other jurisdictions and may be directly contributing to the higher rate reported in our study [17] .
Our relative increase in VTE risk among dialysis patients compared with matched individuals of the general population is comparable to previous findings. Ocak et al. [10] reported an incidence of VTE 5.6 times higher in the dialysis population compared with an age-and sex-matched general population sample, which is similar to our results (HR 4.5). The USRDS study by Tveit et al. [11] reported an incidence of PE that was six times higher than the expected incidence in the general population compared with our HR of 4.7. Possible reasons for the lower relative risk and higher crude risk of VTE and PE in our study compared with prior reports are a higher baseline risk Cox proportional hazards regression models, stratified on matched sets, were used to calculate the HR with 95% CI for the outcomes. c Adjusted for rural location (urban referent), income quintile (1 as the referent, missing values coded as 3) , myocardial infarction (y/n), ischemic stroke (y/n), hypertension (y/n), diabetes (y/n), peripheral vascular disease (y/n), atrial fibrillation (y/n), prior major bleed (y/n), prior VTE (y/n), history of cancer (y/n), recent surgery (y/n), recent fracture (y/n), active smoking (y/n), chronic obstructive pulmonary disease (y/n), congestive heart failure (y/n), dialysis access (central venous catheter, AV fistula/graft, PD catheter) and dialysis modality (HD/PD). of VTE in our general population sample, differences in the sensitivity/specificity of VTE ascertainment between studies and increasing awareness of VTE among physicians.
The increased risk of VTE observed among dialysis patients is likely multifactorial. Our dialysis patient population had a much higher prevalence of comorbidities compared with the matched general population. Several comorbidities, such as prior cancer, prior VTE and congestive heart failure, are known risk factors for VTE [18, 19] . However, the increased VTE risk, while attenuated, persisted even upon adjustment for these factors. Patients with CKD have also been found to display features of hypercoagulability [1, 20] . As well, the use of erythropoiesis stimulating agents to treat CKD-related anemia may increase the risk of VTE [21] . The high prevalence of CVC use is also likely a contributor. CVC-associated thrombi have been described [22, 23] . As well, patients initiating dialysis with a CVC are known to have an increased risk of adverse outcomes [24] .
In support of the high risk associated with CVC use, we report a higher VTE risk among dialysis patients with a CVC compared with an AV fistula/graft or patients on PD. When an outcome of DVT was examined separately, a similar result was found. When an outcome of PE was examined separately, PD patients remained at lower risk but no statistically significant difference was found for HD patients with a CVC or AV fistula/ graft. This finding could potentially be due in part to a lack of power [smaller number of HD patients with an AV fistula/graft and a small number of PE events in this subgroup (n ¼ 16)]. Prior data with respect to dialysis modality and VTE risk are conflicting. One study found an increased risk among HD patients (although not statistically significant) [10] and the other found an increased risk among PD patients [25] . A history of recent hospitalization or immobility is a known risk factor for VTE [18, 19] ; however, we found no increase in VTE among dialysis patients with a hospitalization in the 90 days prior to dialysis initiation. Dialysis patients with a history of strong risk factors for VTE (i.e. provoked VTE) had a higher incidence of VTE. We also found that the incidence of VTE was stable across age strata, which was somewhat unexpected, as prior data would suggest that the incidence increases with age [10, 25] .
As expected, we found that dialysis patients who developed a VTE, compared with dialysis patients who did not, were more likely to experience a major bleed, potentially secondary to anticoagulants prescribed for the treatment of VTE. We also found that dialysis patients who developed a VTE, compared with dialysis patients who did not, were more likely to die. This may be secondary to complications from the VTE itself, i.e. death from a PE or death from a major bleed due to anticoagulants. Prior studies have shown that patients with an abnormal eGFR are at increased risk for fatal bleeds and fatal pulmonary emboli [9, [25] [26] [27] . The observed increased risk of major bleeds and death among dialysis patients with a VTE may also be due to a higher comorbidity burden. We adjusted for demographics and multiple medical conditions, but there is always the possibility for residual confounding.
Our study's primary strength is the fact that it included a large, incident dialysis cohort with information on all health care encounters, minimizing concerns about selection and information biases. However, there are important limitations worth noting. Our study was conducted using administrative data and was retrospective, which means that certain data were lacking. Unfortunately, we did not have data on cause of death or comprehensive data on medication use, particularly anticoagulants. We did not have imaging data, such as Doppler ultrasound and computed tomography pulmonary angiography, to confirm a diagnosis of VTE. We determined an outcome of VTE using administrative diagnostic codes with a reduced sensitivity, so our results likely represent an underestimate of the true incidence of disease [28, 29] . Diagnostic codes for VTE have been found to have a sensitivity of 75.0% (95% CI 69.2-80.2%), a specificity of 93.8% (95% CI 92.2-95.1%) and a positive predictive value ranging from 65% to 95% [29, 30] . Diagnostic codes for our secondary outcome of major bleeding have a sensitivity of 93%, a specificity of 88% and a positive predictive value of 91% [31] .
In conclusion, our data highlight the high risk of VTE among incident dialysis patients, in particular during the first 6 months following dialysis initiation and among patients initiating HD with a catheter. The presence of a VTE confers a high risk of subsequent VTE recurrence, major bleeding or allcause mortality. Further study is needed to elicit the causal mechanisms of the heightened VTE risk, along with the role of thromboprophylaxis, and optimal treatment strategies in dialysis patients.
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